These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 1388090)
1. Efficacy of ondansetron against nausea and vomiting caused by dacarbazine-containing chemotherapy. Legha SS; Hodges C; Ring S Cancer; 1992 Oct; 70(7):2018-20. PubMed ID: 1388090 [TBL] [Abstract][Full Text] [Related]
2. Comparison of ondansetron and ondansetron plus dexamethasone as antiemetic prophylaxis during cisplatin-containing chemotherapy. Smith DB; Newlands ES; Rustin GJ; Begent RH; Howells N; McQuade B; Bagshawe KD Lancet; 1991 Aug; 338(8765):487-90. PubMed ID: 1714532 [TBL] [Abstract][Full Text] [Related]
3. [Novel pharmacologic form of ondansetron (Zofran)--lingual tablets in the prevention of cytostatic chemotherapy-induced loss of appetite, nausea and vomiting]. Gershanovich ML; Beresneva IA; Makhnova EV Vopr Onkol; 2003; 49(4):505-9. PubMed ID: 14569947 [TBL] [Abstract][Full Text] [Related]
4. Ondansetron; further progress in the prevention of nausea and vomiting induced by anti-cancer chemotherapy. Sagar SM; Bayliss MA; Chong SL; Retsas S Clin Oncol (R Coll Radiol); 1991 May; 3(3):183. PubMed ID: 1829958 [No Abstract] [Full Text] [Related]
5. Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. A multicenter, randomized, double-blind, crossover study. De Mulder PH; Seynaeve C; Vermorken JB; van Liessum PA; Mols-Jevdevic S; Allman EL; Beranek P; Verweij J Ann Intern Med; 1990 Dec; 113(11):834-40. PubMed ID: 2146911 [TBL] [Abstract][Full Text] [Related]
6. Ondansetron reduces chemotherapy induced nausea and vomiting refractory to standard antiemetics. Mitchell PL; Evans BD; Allan SG; Forgeson GV; Mak D; Neave L; Humm G; Langley G; Dickson D; Harvey VJ N Z Med J; 1992 Mar; 105(929):73-5. PubMed ID: 1532054 [TBL] [Abstract][Full Text] [Related]
7. A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy. Bonneterre J; Chevallier B; Metz R; Fargeot P; Pujade-Lauraine E; Spielmann M; Tubiana-Hulin M; Paes D; Bons J J Clin Oncol; 1990 Jun; 8(6):1063-9. PubMed ID: 2140854 [TBL] [Abstract][Full Text] [Related]
8. Course, patterns, and risk-factors for chemotherapy-induced emesis in cisplatin-pretreated patients: a study with ondansetron. du Bois A; Meerpohl HG; Vach W; Kommoss FG; Fenzl E; Pfleiderer A Eur J Cancer; 1992; 28(2-3):450-7. PubMed ID: 1534250 [TBL] [Abstract][Full Text] [Related]
9. A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy. Hainsworth J; Harvey W; Pendergrass K; Kasimis B; Oblon D; Monaghan G; Gandara D; Hesketh P; Khojasteh A; Harker G J Clin Oncol; 1991 May; 9(5):721-8. PubMed ID: 1826739 [TBL] [Abstract][Full Text] [Related]
10. Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy. Perez EA; Lembersky B; Kaywin P; Kalman L; Yocom K; Friedman C Cancer J Sci Am; 1998; 4(1):52-8. PubMed ID: 9467047 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of three oral dosages of ondansetron in the prevention of nausea and emesis associated with cyclophosphamide-doxorubicin chemotherapy. Fraschini G; Ciociola A; Esparza L; Templeton D; Holmes FA; Walters RS; Hortobagyi GN J Clin Oncol; 1991 Jul; 9(7):1268-74. PubMed ID: 1828499 [TBL] [Abstract][Full Text] [Related]
12. The influence of dexamethasone in the decrease of chemotherapy-induced nausea and vomiting. Sarcev T; Secen N; Povazan Dj; Sabo A; Popovic J; Bursac D; Kakas M; Zaric B; Milovancev A J BUON; 2007; 12(2):245-52. PubMed ID: 17600880 [TBL] [Abstract][Full Text] [Related]
13. [Ondansetron (GR 38032F), a competitive 5-HT3 receptor antagonist as an antiemetic in cytostatic drug-induced nausea and vomiting. An open, substance-oriented phase II/III study]. Serve H; Perker M; Ertl A; Reichold M; Fink U; Berdel WE Onkologie; 1990 Oct; 13(5):369-74. PubMed ID: 2150552 [TBL] [Abstract][Full Text] [Related]
14. Oral ondansetron (GR38032F) for the control of acute and delayed cyclophosphamide-induced emesis. Rosso R; Campora E; Cetto G; Fosser V; Marangolo M; Oliva C Anticancer Res; 1991; 11(2):937-9. PubMed ID: 1829602 [TBL] [Abstract][Full Text] [Related]
15. Ondansetron. Therapeutic use as an antiemetic. Milne RJ; Heel RC Drugs; 1991 Apr; 41(4):574-95. PubMed ID: 1711961 [TBL] [Abstract][Full Text] [Related]
16. Oral ondansetron for the control of delayed emesis after cisplatin. Report of a phase II study and a review of completed trials to manage delayed emesis. Kris MG; Tyson LB; Clark RA; Gralla RJ Cancer; 1992 Aug; 70(4 Suppl):1012-6. PubMed ID: 1386282 [TBL] [Abstract][Full Text] [Related]
17. [Anti-emetic effect of ondansetron in cisplatin induced nausea and vomiting--a randomized clinical trial]. Zeng WY Zhonghua Zhong Liu Za Zhi; 1992 Jul; 14(4):273-5. PubMed ID: 1396075 [TBL] [Abstract][Full Text] [Related]
18. Ondansetron--the first of a new class of antiemetic agents. Chaffee BJ; Tankanow RM Clin Pharm; 1991 Jun; 10(6):430-46. PubMed ID: 1829668 [TBL] [Abstract][Full Text] [Related]
20. Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting. Cubeddu LX; Hoffmann IS; Fuenmayor NT; Finn AL N Engl J Med; 1990 Mar; 322(12):810-6. PubMed ID: 1689807 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]